Acura jumps 18.1% on Pfizer's Oxecta marketing plan
This article was originally published in Scrip
Executive Summary
Acura Pharmaceuticals closed 18.1% higher on 1 July as the Palatine, Illinois-based company's stock traded at almost 10 times its normal volume following the news that Pfizer will expand its commercial program for the proprietary oxycodone formulation Oxecta.